Idiopathic pulmonary fibrosis differential diagnosis: Difference between revisions
(Created page with "__NOTOC__ {{Idiopathic pulmonary fibrosis }} {{CMG}} ==Overview== ==Differentiating Idiopathic Pulmoary Fibrosis from other Disease== The key issue facing clinicians is whethe...") |
(No difference)
|
Revision as of 19:27, 25 September 2012
|
Idiopathic pulmonary fibrosis Microchapters |
|
Differentiating Idiopathic pulmonary fibrosis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Idiopathic pulmonary fibrosis differential diagnosis On the Web |
|
American Roentgen Ray Society Images of Idiopathic pulmonary fibrosis differential diagnosis |
|
Idiopathic pulmonary fibrosis differential diagnosis in the news |
|
Blogs on Idiopathic pulmonary fibrosis differential diagnosis |
|
Directions to Hospitals Treating Idiopathic pulmonary fibrosis |
|
Risk calculators and risk factors for Idiopathic pulmonary fibrosis differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Differentiating Idiopathic Pulmoary Fibrosis from other Disease
The key issue facing clinicians is whether the presenting history, symptoms/signs, radiology, and pulmonary function testing are collectively in keeping with the diagnosis of IPF (which carries the relatively poor prognosis described above) or whether the findings are due to another process. It has long been recognized that patients with interstitial lung disease related to asbestos exposure, drugs (particularly chemotherapeutic agents), a connective tissue disease, or other diseases may have features that are difficult to distinguish from IPF. Important differential diagnostic considerations include asbestosis; interstitial lung disease related to scleroderma, mixed connective tissue disease, or rheumatoid arthritis; advanced sarcoidosis, hypersensitivity pneumonitis, or Langerhans cell histiocytosis; chronic pulmonary aspiration; radiation-induced fibrosis; as well as previous therapy with cyclophosphamide, nitrofurantoin, methotrexate, and other drugs.
When diagnostic uncertainty remains, a surgical lung biopsy may be required to establish the diagnosis. Generally, lung biopsy is only undertaken when it is deemed that its risks are outweighed by the potential benefits of identifying a disease process that may be amenable to a treatment that the patient would likely be able to tolerate.
The 2002 American Thoracic Society/European Respiratory Society Consensus Guidelines on the Idiopathic Interstitial Pneumonias have formalized criteria for situations in which it is possible to establish the diagnosis of IPF without a lung biopsy.